Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer
October 07, 2015 at 07:05 AM EDT
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it has signed a three-year contract with Tufts Health Plan through which the ...
